Rim Joubran, MD
Endocrinology, Diabetes & Metabolism · Melrose Park, ILNPI 1164489241
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,545 of the $18,735 with a category attached, or 61.6%. Johnson & Johnson accounts for 64.4% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $10,849 and has fallen 88.4% since, to $1,261 in 2025.
Across 288 payments — averaging $65.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- Novo Nordisk$851
- Sanofi-aventis U.S. LLC$817
- Amgen$680
- Dexcom, Inc.$408
- BETA Bionics, Inc.$346
- plus $4K from 36 others
Across 1 payment — averaging $375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diabetes Care, Inc.$375
What the payments were for
- Speaking & faculty fees$11,54562%
- Travel & lodging$1941%
- Food & beverage$6,85637%
- Education$800%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$11,778
- iLet Bionic Pancreas$816
- SOLIQUA 100/33$400
- Ozempic$246
- TZIELD$131
- iLet Insulin Infusion Kit Inset$125
- iLet Insulin Infusion Kit Contact Detach$125
- Yorvipath$124
- CRYSVITA$124
- EVENITY$118
- InPen$112
How this compares
$18,735 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 417 | $487,724 |
| JardianceEmpagliflozin | 318 | $279,279 |
| MounjaroTirzepatide | 101 | $141,647 |
| TrulicityDulaglutide | 108 | $122,449 |
| ProliaDenosumab | 66 | $115,811 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 71 | $67,486 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 60 | $54,911 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $52,474 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 45 | $44,514 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 100 | $44,144 |
| RybelsusSemaglutide | 27 | $43,773 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $36,086 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $34,572 |
| JanuviaSitagliptin Phosphate | 15 | $18,937 |
| FiaspInsulin Aspart (Niacinamide) | 17 | $17,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $851 | $554,268494 claims |
| Boehringer IngelheimJardiance, Tradjenta | $274 | $294,128338 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $187 | $276,683272 claims |
| AmgenProlia | $680 | $115,81166 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $817 | $34,57237 claims |
| MerckJanuvia | $15 | $18,93715 claims |
| AbbVieSynthroid | $102 | $14,368160 claims |
| AstraZenecaFarxiga | $285 | $12,05516 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $117 | $5,289477 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Melrose Park
- Maha AbboudMelrose Park$219K
- Terri WashingtonMelrose Park$48K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.